Nowadays non-healing wounds are diagnosed de facto, when the wound doesn't heal longer than 20 days. This results in subjective wound management and in inappropriate therapy. The diagnosis of non-healing wound is a challenge, because of their unpredictable nature. Moreover, there is no single biomarker for diagnosis of such kind of disease. All this together impedes the development of point-of-care diagnostic systems for the wound. We performed a thorough literature review of proteomic studies of wound exudate, and suggested the investigation object – several low and high abundant proteins, which are typical for healing and non-healing wounds. Based on this choice, we designed prove-of-the-concept studies, in which the first stage is the development of the biosensor-on-chip analytical platform (BioCAP) based on imaging SPR. The development stages of BioCAP include: microstructurization of the SPR substrate by alkanethiols with microcontact printing (μCP) technique forming self-assembled monolayer (SAM) of protein-repellent coatings and deposition of functional SAM of thiols with ion-chelating tris-nitrilotriacetic acid (trisNTA) group; immobilization of antibodies on the same chip with His-tagged protein A (SpA). At the current stage of the research we optimized the conditions for μCP and for the SpA immobilization. Such developed protocols allowed to perform 20 and more SpA re-immobilization cycles with possibility to capture desired antibody depending on the selected antigen using only one chip without sophisticated regeneration of its surface. Futher development of the BioCAP by the integrating of a microfluidic system will allow us to form the micropaterns of at least 4 different antibodies for wound biomarker detection.